Peer-Reviewed Publication INSERM (Institut national de la santé et de la recherche médicale) Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population. The disease spans from benign fat accumulation in the liver (steatosis) to its more severe form, metabolic dysfunction-associated steatohepatitis...
Post
Study links high-fiber diet to delayed progression of blood cancer
by Memorial Sloan Kettering Cancer Center Credit: Unsplash/CC0 Public Domain Researchers at Memorial Sloan Kettering Cancer Center (MSK) have reported results from the first-ever clinical trial demonstrating that a high-fiber, plant-based dietary intervention may delay progression to multiple myeloma, a rare and incurable blood cancer affecting the bone marrow. The study enrolled 20 participants with a precancerous blood...
Post
Hair growth drug safe at low doses for breast cancer patients
Peer-Reviewed Publication NYU Langone Health / NYU Grossman School of Medicine Hair loss during chemotherapy can cause enough distress for some women to lose self-confidence, which experts say may discourage them from seeking chemotherapy in the first place. Oral minoxidil is a commonly prescribed treatment for hair loss. The drug is also the active ingredient...
Post
Sugary drinks significantly raise cardiovascular disease risk, but occasional sweet treats don’t, scientists find
by Frontiers Credit: Pixabay/CC0 Public Domain A little of what you fancy does you good… unless it’s a fizzy drink. Scientists studying the impact of sugar on the risk of cardiovascular disease have found that eating too much added sugar increases your risk of stroke or aneurysm, but eating a few treats is associated with a...
Post
New AI stroke brain scan readings are twice as accurate as current method
by Samantha Rey06 December 2024 view large AI pinpoints stroke timing, treatment potential from a single scan New AI software can read the brain scans of patients who have had a stroke, to more accurately pinpoint when it happened and help doctors work out whether it can be successfully treated. It is hoped that the new...
Post
Neuroscientists discover a new pathway to forming long-term memories in the brain
by Max Planck Florida Institute for Neuroscience Scientists discover a new pathway to long-term memory formation in the brain that can bypass the formation of short-term memory. Credit: Helena Pinheiro Researchers from Max Planck Florida Institute for Neuroscience have discovered a new pathway to forming long-term memories in the brain. Their work, published in Nature Neuroscience, suggests that long-term...
Post
Serious side effect of using CRISPR-Cas gene scissors uncovered: AZD7648 molecule can destroy parts of genome
by Peter Rüegg, ETH Zurich Credit: Pixabay/CC0 Public Domain Genome editing with various CRISPR-Cas molecule complexes has progressed rapidly in recent years. Hundreds of labs around the world are now working to put these tools to clinical use and are continuously advancing them. CRISPR-Cas tools allow researchers to modify individual building blocks of genetic material in...
Post
Some people say they have a high pain threshold. Here’s why
by Joshua Pate and Tory Madden, The Conversation Credit: Mikhail Nilov from Pexels We’ve all heard someone claim they have a “high pain threshold” as if it’s a mark of strength or resilience. But does science support the idea that some people genuinely feel less pain than others? Pain is an experience shaped by our psychology...
Post
Repurposed drug has promising efficacy in non-small cell lung cancer
by UT Southwestern Medical Center UT Southwestern researchers (l-r) Farjana Fattah, Ph.D., Mitchell S. von Itzstein, M.D., David E. Gerber, M.D., and Kelly Kyle, B.S., discovered a drug that shows promise in treating non-small cell lung cancer with KRAS mutations. Credit: UT Southwestern Medical Center An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in...
Post
LBCL: Bispecific Antibodies Fare Less Well in Real-World Analysis
Randy Dotinga December 07, 2024 01 SAN DIEGO — Compared with clinical trials, a real-world retrospective analysis has linked the bispecific antibodies epcoritamab (Epkinly) and glofitamab (Columvi) to somewhat poorer outcomes in relapsed or refractory large B-cell lymphoma (LBCL). In a presentation here at the American Society of Hematology (ASH) 2024 Annual Meeting, researchers reported that of 172 patients treated with the...